218 related articles for article (PubMed ID: 36727298)
1. The CTLA-4 immune checkpoint protein regulates PD-L1:PD-1 interaction via transendocytosis of its ligand CD80.
Kennedy A; Robinson MA; Hinze C; Waters E; Williams C; Halliday N; Dovedi S; Sansom DM
EMBO J; 2023 Mar; 42(5):e111556. PubMed ID: 36727298
[TBL] [Abstract][Full Text] [Related]
2. Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells.
Tekguc M; Wing JB; Osaki M; Long J; Sakaguchi S
Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34301886
[TBL] [Abstract][Full Text] [Related]
3. PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways.
Zhao Y; Lee CK; Lin CH; Gassen RB; Xu X; Huang Z; Xiao C; Bonorino C; Lu LF; Bui JD; Hui E
Immunity; 2019 Dec; 51(6):1059-1073.e9. PubMed ID: 31757674
[TBL] [Abstract][Full Text] [Related]
4. By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1.
Kleinpeter P; Remy-Ziller C; Winter E; Gantzer M; Nourtier V; Kempf J; Hortelano J; Schmitt D; Schultz H; Geist M; Brua C; Hoffmann C; Schlesinger Y; Villeval D; Thioudellet C; Erbs P; Foloppe J; Silvestre N; Fend L; Quemeneur E; Marchand JB
J Virol; 2019 Jun; 93(11):. PubMed ID: 30918073
[TBL] [Abstract][Full Text] [Related]
5. Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.
Le Goux C; Damotte D; Vacher S; Sibony M; Delongchamps NB; Schnitzler A; Terris B; Zerbib M; Bieche I; Pignot G
Urol Oncol; 2017 May; 35(5):257-263. PubMed ID: 28291636
[TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint PD-1/PD-L1 CTLA-4/CD80 are Blocked by
Li W; Kim TI; Kim JH; Chung HS
Molecules; 2019 Nov; 24(22):. PubMed ID: 31717574
[TBL] [Abstract][Full Text] [Related]
7. Impact of CTLA-4 checkpoint antibodies on ligand binding and Transendocytosis.
Williams C; Kennedy A; Robinson MA; Lloyd C; Dovedi SJ; Sansom DM
Front Immunol; 2022; 13():871802. PubMed ID: 36119113
[TBL] [Abstract][Full Text] [Related]
8. Differences in CD80 and CD86 transendocytosis reveal CD86 as a key target for CTLA-4 immune regulation.
Kennedy A; Waters E; Rowshanravan B; Hinze C; Williams C; Janman D; Fox TA; Booth C; Pesenacker AM; Halliday N; Soskic B; Kaur S; Qureshi OS; Morris EC; Ikemizu S; Paluch C; Huo J; Davis SJ; Boucrot E; Walker LSK; Sansom DM
Nat Immunol; 2022 Sep; 23(9):1365-1378. PubMed ID: 35999394
[TBL] [Abstract][Full Text] [Related]
9. In Vitro Analysis of CTLA-4-Mediated Transendocytosis by Regulatory T Cells.
Waters E; Williams C; Kennedy A; Sansom DM
Methods Mol Biol; 2023; 2559():171-187. PubMed ID: 36180633
[TBL] [Abstract][Full Text] [Related]
10. Targeting CD28, CTLA-4 and PD-L1 costimulation differentially controls immune synapses and function of human regulatory and conventional T-cells.
Dilek N; Poirier N; Hulin P; Coulon F; Mary C; Ville S; Vie H; Clémenceau B; Blancho G; Vanhove B
PLoS One; 2013; 8(12):e83139. PubMed ID: 24376655
[TBL] [Abstract][Full Text] [Related]
11. The fusion of quantitative molecular proteomics and immune-oncology: a step towards precision medicine in cancer therapeutics.
Miles J; Ward SG; Larijani B
FEBS Lett; 2022 Nov; 596(21):2721-2735. PubMed ID: 36002439
[TBL] [Abstract][Full Text] [Related]
12. miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint.
Xu S; Tao Z; Hai B; Liang H; Shi Y; Wang T; Song W; Chen Y; OuYang J; Chen J; Kong F; Dong Y; Jiang SW; Li W; Wang P; Yuan Z; Wan X; Wang C; Li W; Zhang X; Chen K
Nat Commun; 2016 May; 7():11406. PubMed ID: 27147225
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 Binds to B7-1 Only
Chaudhri A; Xiao Y; Klee AN; Wang X; Zhu B; Freeman GJ
Cancer Immunol Res; 2018 Aug; 6(8):921-929. PubMed ID: 29871885
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 signaling selectively regulates T cell lymphatic transendothelial migration.
Piao W; Li L; Saxena V; Iyyathurai J; Lakhan R; Zhang Y; Lape IT; Paluskievicz C; Hippen KL; Lee Y; Silverman E; Shirkey MW; Riella LV; Blazar BR; Bromberg JS
Nat Commun; 2022 Apr; 13(1):2176. PubMed ID: 35449134
[TBL] [Abstract][Full Text] [Related]
15. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
[TBL] [Abstract][Full Text] [Related]
16. Investigation of the potential effects of estrogen receptor modulators on immune checkpoint molecules.
Abramenko N; Vellieux F; Veselá K; Kejík Z; Hajduch J; Masařík M; Babula P; Hoskovec D; Pacák K; Martásek P; Smetana K; Jakubek M
Sci Rep; 2024 Feb; 14(1):3043. PubMed ID: 38321096
[TBL] [Abstract][Full Text] [Related]
17. Dimers Aren't Forever: CD80 Breaks up with PD-L1.
Sansom DM; Walker LSK
Immunity; 2019 Dec; 51(6):972-974. PubMed ID: 31951541
[TBL] [Abstract][Full Text] [Related]
18. Identification, binding, and structural characterization of single domain anti-PD-L1 antibodies inhibitory of immune regulatory proteins PD-1 and CD80.
Kang-Pettinger T; Walker K; Brown R; Cowan R; Wright H; Baravalle R; Waters LC; Muskett FW; Bowler MW; Sawmynaden K; Coombs PJ; Carr MD; Hall G
J Biol Chem; 2023 Jan; 299(1):102769. PubMed ID: 36470427
[TBL] [Abstract][Full Text] [Related]
19. Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity.
Zhang Y; Song Q; Cassady K; Lee M; Tang H; Zheng M; Wang B; Schones DE; Fu YX; Riggs AD; Martin PJ; Feng R; Zeng D
Proc Natl Acad Sci U S A; 2023 Apr; 120(16):e2205085120. PubMed ID: 37036990
[TBL] [Abstract][Full Text] [Related]
20. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer.
Zhang H; Dai Z; Wu W; Wang Z; Zhang N; Zhang L; Zeng WJ; Liu Z; Cheng Q
J Exp Clin Cancer Res; 2021 Jun; 40(1):184. PubMed ID: 34088360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
